Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis

dc.authorwosidKarakurt, Melek / AAO-5495-2020
dc.contributor.authorKarakurt Eryılmaz, Melek
dc.contributor.authorKaraağaç, Mustafa
dc.date.accessioned2021-11-01T15:01:57Z
dc.date.available2021-11-01T15:01:57Z
dc.date.issued2019
dc.department[Belirlenecek]
dc.description.abstractAbiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
dc.identifier.doi10.1177/1078155218818250
dc.identifier.endpage2034en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue8en_US
dc.identifier.pmid31694496
dc.identifier.scopus2-s2.0-85074625126
dc.identifier.scopusqualityQ3
dc.identifier.startpage2031en_US
dc.identifier.urihttps://doi.org/10.1177/1078155218818250
dc.identifier.urihttps://hdl.handle.net/11491/6781
dc.identifier.volume25en_US
dc.identifier.wosWOS:000494855400030
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKarakurt Eryılmaz, Melek
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofJournal Of Oncology Pharmacy Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAbirateroneen_US
dc.subjectmetastatic castration-resistant prostate canceren_US
dc.subjecthemodialysisen_US
dc.titleAbiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis
dc.typeArticle

Dosyalar